Liver-stage antigen 1 and Liver-stage associated protein 2 (LSA1 and LSAP2)

Liver-stage antigen 1 (LSA1) and liver-stage associated protein 2 (LSAP2) are proteins expressed by *Plasmodium falciparum* parasites during their development in the liver (liver-stage of the malaria lifecycle)[1][5]. Both are considered promising antigens for malaria vaccine development, as responses to these antigens can induce protective immunity in preclinical models. LSA1 is well-conserved and essential for late liver-stage parasite development, while LSAP2 has shown strong immunogenicity. They are not classical drug targets but serve as key targets in subunit vaccine strategies designed to elicit cellular immune responses that prevent liver-stage parasite replication and block the progression to blood-stage malaria[1][5][6]. Vaccines under development, such as viral-vector vaccines encoding LSA1 and LSAP2, have shown enhanced efficacy by stimulating both T cell and humoral responses. There are no known drugs that target these antigens directly; their clinical utility remains investigational in the context of malaria vaccine development.

Other names

PfLSA1 (Plasmodium falciparum liver-stage antigen 1)PfLSAP2 (Plasmodium falciparum liver-stage associated protein 2)Liver-stage antigen I (for LSA1)Liver-stage associated protein II (for LSAP2)

As subunit vaccine antigens, LSA1 and LSAP2 are expressed by the malaria parasite during the liver stage and are recognized by the host immune system; vaccines using these induce antigen-specific CD8+ T cell responses that can mediate pre-erythrocytic (liver-stage) immunity, potentially preventing parasite progression to symptomatic blood-stage malaria[1][5][6].